Abstract 669P
Background
Tumor-targeted drug delivery technologies are urgently needed to overcome conventional chemotherapy’s lack of tumor selectivity. Alphalex conjugates, which contain a pH-low insertion peptide (pHLIP), a linker and a payload are designed to overcome this lack of selectivity. Alphalex PDCs target tumors in an antigen-independent manner. At pH 7.4, the peptide is unstructured. In the low pH tumor microenvironment the peptide forms an alpha helix and inserts directionally into the tumor cell membrane delivering the linker and payload. For CBX-12 the payload is exatecan.
Methods
In this Phase 1 trial, cohorts of pts were treated with escalating doses of CBX-12 in a 3 + 3 design. The primary objectives are safety, tolerability and to determine the MTD/RP2D. Secondary and exploratory objectives include evaluation of plasma PK of CBX-12 and exatecan, anti-tumor activity per RECIST v1.1, and measurement of anti-drug antibodies.
Results
Enrollment is complete with 69 pts having been treated on study. The most frequent treatment-related AEs (TRAEs) were anaemia (53.6%), leukopenia (42.0%), neutropenia (40.6%), nausea (39.1%), and fatigue (36.2%). The most frequent Gr3/4 TRAEs were neutropenia, (27.5%), anaemia (24.6%), leukopenia (21.7%), and thrombocytopenia (13.0%). No ILD or ophthalmic toxicity was reported. There were 5 confirmed responses in ovarian (2), breast (2), and colorectal cancer (1). Evidence of activity was also seen in NSCLC, cholangiocarcinoma, and thymic cancer. Of 12 patients with ovarian cancer there was one confirmed complete response, one confirmed partial response (PR) and tw0 unconfirmed PRs. 8 of 12 saw clinical benefit. The RP2D was established as 125mg/m2 every 21 days.
Conclusions
Tumor targeting facilitated by this pH sensitive peptide made possible an improved safety profile despite the administration of a 5-fold increase in the dose of exatecan compared to unconjugated exatecan. The dose limiting toxicity is myelosuppression. CBX-12 demonstrated broad activity with 5 confirmed responses in three malignancies. A randomized Phase 2 study in platinum resistant ovarian cancer is underway comparing two doses on the once every 21 day schedule.
Clinical trial identification
NCT04902872.
Editorial acknowledgement
Legal entity responsible for the study
Cybrexa Inc.
Funding
Cybrexa Inc.
Disclosure
F. Meric-Bernstam: Financial Interests, Personal and Institutional, Funding: Cybrexa, Inc. P. Pearson: Financial Interests, Personal, Financially compensated role, Consultant: Cybrexa, Inc. M.N. Needle: Financial Interests, Personal, Full or part-time Employment: Cybrexa, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
630P - Debio 0123 + carboplatin (CP) for patients (pts) with advanced solid tumors: Safety, preliminary efficacy and determination of recommended phase II dose (RP2D)
Presenter: Hans Gelderblom
Session: Poster session 01
631P - Phase Ib expansion study of CX-5461 in patients with solid tumours and BRCA2 and/or PALB2 mutation
Presenter: Pamela Soberanis Pina
Session: Poster session 01
632P - Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 01
633P - First-in-human dose-escalation study of basroparib (STP1002) in patients with advanced-stage solid tumors
Presenter: Christopher Lieu
Session: Poster session 01
634P - First results from phase I/II study of CTS2190, a novel small-molecule inhibitor of type I PRMTs, in patients with advanced solid tumors
Presenter: Xiangdong Cheng
Session: Poster session 01
635P - The phase I dose-escalation study of TSN084, a multi-kinase inhibitor, in patients with advanced malignant tumors
Presenter: Jie Wang
Session: Poster session 01
636P - Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy
Presenter: Benjamin Kong
Session: Poster session 01
637P - AC699, a novel chimeric estrogen receptor degrader, in a phase I study in breast cancer
Presenter: Erika Hamilton
Session: Poster session 01
638P - Final results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center
Presenter: Apostolia Maria Tsimberidou
Session: Poster session 01
639P - Serial ctDNA profiling as a catalyst for tailored therapeutics in advanced cancer: Analysis of two precision medicine studies
Presenter: Sophie Cousin
Session: Poster session 01